Brain ischaemia, calcium and calcium antagonists

Area of Science:

• Neuroscience
• Mitochondrial Biology
• Ischemia Research

Background:

• Cerebral ischemia leads to mitochondrial dysfunction, characterized by loss of respiratory activity.
• Similar mitochondrial dysfunction is observed following in vitro incubation with calcium ions (Ca2+).
• This suggests a potential role for Ca2+ in the cellular damage during ischemia.

Purpose of the Study:

• To investigate the role of Ca2+ in the pathogenesis of cerebral ischemia.
• To evaluate the efficacy of Ca2+ antagonists in reversing ischemia-induced mitochondrial dysfunction.

Main Methods:

• Comparison of respiratory activity in cerebral mitochondria subjected to in vivo ischemia versus in vitro Ca2+ exposure.
• In vitro studies using Ca2+ antagonists (diltiazem, nifedipine, perhexiline, verapamil) to assess their effect on isolated ischemic brain mitochondria.

Main Results:

• A strong similarity was found between mitochondrial activity loss due to in vivo ischemia and in vitro Ca2+ incubation.
• Ca2+ antagonists demonstrated significant vasodilatory action in vitro.
• However, these Ca2+ antagonists failed to reverse the loss of functional activity in isolated mitochondria from ischemic brain tissue.

Conclusions:

• Calcium ions (Ca2+) are implicated in the cellular changes associated with cerebral ischemia.
• Ca2+ antagonists are not effective in treating primary focal cerebral ischemia by restoring mitochondrial function.
• Ca2+ antagonists may hold therapeutic potential for cerebral ischemia secondary to vasospasm due to their vasodilatory properties.